When injected into mice with retinal disease, the special retinal blood cells integrated into the damaged tissue to ...

Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, and Nanoscope Therapeutics, a biotechnology company committed to commercializing novel, disease ...

Opus Genetics, Inc. (Nasdaq: IRD) (the “Company”, “Opus Genetics” or “Opus”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients ...

A 6-year-old girl with a rare inherited blindness regained vision through gene therapy, helping her see in low light again.

Life Biosciences has received FDA clearance to begin a first-in-human Phase 1 clinical trial of ER-100, a gene therapy ...

Quantified preferences favored higher lesion growth rate reduction (10%→50% at 18 months) as the primary driver across all ...

Opus Genetics, Inc. (Nasdaq: IRD) (the "Company", "Opus Genetics" or "Opus"), a clinical-stage biopharmaceutical company developing gene ...

To circumvent the unreliability of animal models, which often fail to mirror human retinal biology due to vast physiological disparities, Russian researchers have successfully cultivated living ...

The Foundation Fighting Blindness and its venture arm, the RD Fund (Retinal Degeneration Fund), today announced a $1 million commitment from A Race Against Blindness (RAB) to advance gene-agnostic ...

Estimated global prevalence is 21,800 patients, including 8,400 patients in the U.S. comprised of approximately 8,000 best vitelliform macular dystrophy (BVMD) and approximately 400 autosomal ...

Khanani, MD, MA, FASRS, founded Clinical Trials at the Summit (CTS) 6 years ago, the vision was to bring all stakeholders in retinal drug development together under one roof. At this year's meeting, ...

Ocugen has no product revenue, remains loss-making, and the convertible notes add debt burden and potential share dilution.